Phase 3 N=325 An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
Early Alzheimer's Disease
Primary: Primary Cognitive Efficacy Endpoint (ADAS-Cog13) — 4.40; 3.89 Score on a scale — p=0.6058
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=199 The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease
Alzheimer's Disease
Primary: CERAD-K (the Korean Version of the Consortium to Establish a Registry for Alzheimer's Disease) — 8.28; 7.31; 17.86; 10.62 Units on Scale
N/A N=61 Dementia Risk and Dynamic Response to Exercise
Alzheimer Disease 2 Due to Apoe4 Isoform · Healthy Aging
Primary: Cerebral Blood Flow Area Under Curve — 715; 751 mL/100g tissue
N/A N=119 Exercise for Brain Health in the Fight Against Alzheimer's Disease
Healthy Cognition
Primary: Rey Auditory Verbal Learning Test Sum of Trials 1-5 — 49.7; 47.6; 51.6; 49.4 Sum of words recalled Trials 1 to 5
N/A N=148 STIM+: PET Biomarker Education & Disclosure
Mild Cognitive Impairment · Dementia; Alzheimer's Type (Etiology)
Primary: Participant Interest in PET Biomarker Disclosure — 73 Participants
Phase 2 N=128 Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
Alzheimer Disease
Primary: Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. — 0.35; 0.20; 0.26; 0.32 z-score — p=0.3236
Phase 2 N=65 Alzheimer's Disease: Potential Benefit of Isoflavones
Alzheimer's Disease
Primary: Cognitive Outcomes - Language Executive Function : Category Fluency Assessed as Number of Words Generated/Min — 21.5; 25.7 number of words generated per minute
Phase 3 N=131 Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid
Alzheimer's Disease
Primary: Regional Cerebral Blood Flow Using Arterial Spin-labeling MRI — 55.7; 54.5 mL/g/min — p=0.17
N/A N=114 Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Mild Cognitive Impairment
Primary: Geriatric Depression Scale — 2.6; 2.1; 2.8; 1.9 score on a scale
Phase 2 N=20 Effect of Insulin Sensitizer Metformin on AD Biomarkers
Alzheimer's Disease · Vascular Dementia · Dementia
Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled
Phase 2 N=356 A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
Alzheimer Disease
Primary: Disease Progression as Measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score — 1.02; 0.80; 1.07; 1.15 Score on a scale — p=0.7975
Phase 4 N=89 Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease
Genetic Risk for Alzheimer's Disease
Primary: Change in BOLD Response From Baseline to 24 Weeks During Functional Magnetic Resonance Imaging - Left Posterior Cingulate BOLD Signal at 24 Weeks, Adjusting for Baseline…
Phase 3 N=262 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Alzheimers Disease · Dementia · Alzheimers Disease, Familial
Primary: Assess Cognitive Efficacy in Individuals With Mutations Causing Dominantly Inherited AD as Measured by the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE); — 1.063…
Phase 2 N=252 A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort
Alzheimer's Disease
Primary: Period A: Annualized Rate of Change in the Autosomal-Dominant Alzheimer's Disease (API ADAD) Composite Cognitive Test Total Score — -1.10; -1.42 points on scale per year…
Phase 3 N=579 Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline (W0) in Mean ADAS-Cog Total Score at W24 as a Function of APOE e4 Status in Apolipoprotein epsilon4 (APOE e4) Negative Cohort — 1.6; -0.2; 0.6; 0.9…
Phase 2 N=263 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Alzheimer's Disease (AD)
Primary: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) Score at Week 12 — -1.26; -1.28; -1.68; -1.01 score on a scale — p=0.9819
Phase 2 N=124 Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD
Mild Cognitive Impairment · Alzheimer Disease
Primary: Average Maximal Increment of Anti-Aβ40 Antibody Signal (Optical Density [OD] in ELISA) — 0.12; 3.27 OD — p=<0.0001
Phase 3 N=387 A Study of Gantenerumab in Participants With Mild Alzheimer Disease
Alzheimer's Disease
Primary: Part 2: Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) — 91.5; 95.4; 24.8; 38.0 Percentage of Participants
Phase 2 N=13 PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
Alzheimer Disease
Primary: Maximum Plasma Concentration (Cmax) — 1020; 1100 ng/mL
Phase 2 N=64 PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
Alzheimer Disease
Primary: Change From Baseline in CSF Abeta42 — 4.8; 12.5; 16.2 pg/mL — p=0.087
Phase 2 N=50 Riluzole in Mild Alzheimer's Disease
Alzheimer's Disease
Primary: Imaging Biomarkers FDG-PET SUVR in Regions of Interest — -0.048; -0.005; -0.032; -0.007 Standardized Uptake Value Ratios (SUVRs)
Phase 1 N=49 Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease
Alzheimer's Disease · Central Nervous System Diseases
Primary: Safety and Tolerability of Multiple Doses of EVP-6124 or Placebo in Subjects With Alzheimer's Disease — 0; 0; 0; 0 Participants
Phase 2 N=27 Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
Alzheimer's Disease
Primary: Amyloid Deposition Obtained on a 18F-flutemetamol Brain Scan. — 1.65 ratio of flutemetamol absorbed — p=<0.05
Phase 3 N=1,111 Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks — 7.37; 6.77 units on a scale — p=0.560
N/A N=163 New Approach for Treatment of Behavioral Disorders in Alzheimer's Disease (Alzheimer's Behavioral and Cognitive Disorders)
Alzheimer Disease · Behavioral Disorders · Cognitive Impairment
Primary: Evaluations of Behavioral Disorders — 68; 66; 36; 69 Scores on a scale — p=1
N/A N=117 Alzheimer's Prevention Through Exercise
Alzheimer's Disease
Primary: Amyloid Burden — 1.20; 1.22; 1.21; 1.22 Standard Uptake Value Ratio (SUVR)
Phase 2 N=16 Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
Alzheimer Disease
Primary: Number of TEAEs, Related TEAEs, SAEs, and Related SAEs — 6; 11; 4; 7 Participants
N/A N=10 tACS for Amyloid-β Reduction in Alzheimer's Disease
Alzheimer Disease
Primary: Change in Amyloid Burden — -1.55 dSUVR
N/A N=159 Cardiorespiratory Fitness, Apolipoprotein E Genotype, and Cognitive Functions: A Prospective Study
Aging · Cognitive Change
Primary: Changes in Inhibitory Performance: Stroop Task — 1.66; -29.85; 21.49; -20.13 ms
Phase 3 N=1,537 Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks — 6.19; 7.29; 7.68 units on a scale — p=0.134